These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15504218)

  • 41. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.
    Oton E; Barcena R; Moreno-Planas JM; Cuervas-Mons V; Moreno-Zamora A; Barrios C; Garcia-Garzon S; Moreno A; Boullosa-Graña E; Rubio-Gonzalez EE; Garcia-Gonzalez M; Blesa C; Mateos ML
    Am J Transplant; 2006 Oct; 6(10):2348-55. PubMed ID: 16869810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients.
    Dzekova P; Asani A; Selim G; Gelev S; Trajceska L; Amitov V; Selja N; Zabzun M; Mena S; Gaseva M; Sikole A
    Int J Artif Organs; 2009 Mar; 32(3):180-4. PubMed ID: 19440994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prophylaxis and treatment for recurrent hepatitis C virus after liver transplantation].
    Sugawara Y; Makuuchi M
    Nihon Shokakibyo Gakkai Zasshi; 2006 Jun; 103(6):626-30. PubMed ID: 16800284
    [No Abstract]   [Full Text] [Related]  

  • 44. [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure].
    Vallet-Pichard A; Pol S
    Nephrol Ther; 2015 Nov; 11(6):507-20. PubMed ID: 26423779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hepatic transplantation and HBV reinfection].
    Xu X; Lu Z
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):75-6. PubMed ID: 11856518
    [No Abstract]   [Full Text] [Related]  

  • 46. Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization.
    Foruny JR; Bárcena R; Moreno A; Blázquez J; Manzano R; Gil-Grande LA; Moreno A; Nuño J
    Transplantation; 2006 Jul; 82(2):289-90. PubMed ID: 16858295
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment for recurrent hepatitis C virus infection after liver transplantation.
    Balbi E; Leal CR; Pacheco-Moreira LF; Pousa FS; Covelo MC; Gonzalez AC; Oliveira PV; Agoglia L; Roma J; Cariús LP; Enne M
    Transplant Proc; 2009 Apr; 41(3):891-4. PubMed ID: 19376381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cure of acute hepatitis C in HIV co-infection?
    Ristig MB; Tebas P; Gandy I; Qaqish R; Aberg JA
    J Clin Gastroenterol; 2004 Mar; 38(3):303. PubMed ID: 15128087
    [No Abstract]   [Full Text] [Related]  

  • 49. Consensus interferon: tailored therapy and the impact of adherence.
    Gonzalez SA
    Dig Dis Sci; 2011 Mar; 56(3):631-4. PubMed ID: 21259073
    [No Abstract]   [Full Text] [Related]  

  • 50. HBV plus HCV, HCV plus HIV, HBV plus HIV.
    Park JS; Saraf N; Dieterich DT
    Curr Gastroenterol Rep; 2006 Feb; 8(1):67-74. PubMed ID: 16510037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Acute hepatitis C in 2005].
    Nguyen-Khac E
    Gastroenterol Clin Biol; 2005 Nov; 29(11):1149-56. PubMed ID: 16505761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in liver disease. Highlights from the 51st Annual Meeting of the American Association for the Study of Liver Diseases, October 27-31, 2000, Dallas, TX.
    Davis GL; Keeffe EB
    Rev Gastroenterol Disord; 2001; 1(1):42-7. PubMed ID: 12120119
    [No Abstract]   [Full Text] [Related]  

  • 54. HIV and hepatitis co-infection: a consensus for treatment?
    Lumb J
    Lancet Infect Dis; 2005 Apr; 5(4):202. PubMed ID: 15834972
    [No Abstract]   [Full Text] [Related]  

  • 55. [Information for patients. Treatment of acute hepatitis C].
    Otón Nieto E
    Rev Esp Enferm Dig; 2011 Oct; 103(10):549. PubMed ID: 22054273
    [No Abstract]   [Full Text] [Related]  

  • 56. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.
    Saab S; Oh MK; Ibrahim AB; Durazo F; Han S; Yersiz H; Farmer DG; Ghobrial RM; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2007 Jul; 13(7):1032-8. PubMed ID: 17600345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hepatitis C infection among patients receiving hemodialysis].
    Kamar N; Izopet J; Rostaing L
    Nephrologie; 2003; 24(3):133-41. PubMed ID: 12814060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case.
    Takeishi K; Shirabe K; Toshima T; Ikegami T; Morita K; Fukuhara T; Motomura T; Mano Y; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
    Surg Today; 2011 Jul; 41(7):1016-9. PubMed ID: 21748625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
    Reddy KR; Everson GT
    Hepatology; 2013 Sep; 58(3):1181-4. PubMed ID: 23908010
    [No Abstract]   [Full Text] [Related]  

  • 60. Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease.
    Ciccorossi P; Filipponi F; Oliveri F; Coco B; Colombatto P; Giannotti A; Bonino F; Campa M; Mosca F; Brunetto MR
    Transplant Proc; 2003 May; 35(3):1028-9. PubMed ID: 12947846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.